Genmab A/S ADR (GMAB): Price and Financial Metrics
GMAB Price/Volume Stats
| Current price | $28.97 | 52-week high | $42.72 |
| Prev. close | $28.70 | 52-week low | $26.32 |
| Day low | $28.72 | Volume | 452,300 |
| Day high | $29.21 | Avg. volume | 589,447 |
| 50-day MA | $29.34 | Dividend yield | N/A |
| 200-day MA | $32.63 | Market Cap | 19.16B |
GMAB Stock Price Chart Interactive Chart >
Genmab A/S ADR (GMAB) Company Bio
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US. (Source:Wikipedia)
Latest GMAB News From Around the Web
Below are the latest news stories about GENMAB A that investors may wish to consider to help them evaluate GMAB as an investment opportunity.
Genmab to Hold 2023 R&D Update and ASH Data Review MeetingMedia Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 12, 2023 – Genmab A/S (Nasdaq: GMAB) will hold its 2023 R&D Update and ASH Data Review Meeting today, December 12, 2023 at 11:00 AM Eastern Time (5:00 PM CET / 4:00 PM GMT). The event will take place virtually in English and can be attended via live webcast. To register for the webcast, click https://genmab-post-ash-2023.open-exchange.net/. An archive of the webcast will be avai |
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)COPENHAGEN, Denmark, December 09, 2023--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate of 63 percent and minimal residual disease (MRD) negativity rate of 67 percent in patients with relapsed/refractory (R/R) foll |
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) announced today that adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) previously treated with two or more prior therapies experienced strong and durable responses with high overall response (ORR) and complete response (CR) rates when treated with epcoritamab (DuoBody® CD3xCD20), an investigational, subcutaneously administered T-cell engaging bispecific antibody. More than half of patients who responded to treatment in the st |
HRMY or GMAB: Which Is the Better Value Stock Right Now?HRMY vs. GMAB: Which Stock Is the Better Value Option? |
Capital Increase in Genmab as a Result of Employee Warrant ExerciseCompany Announcement COPENHAGEN, Denmark; December 5, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 7,054 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 1,106 shares at DKK 1,025.00,3,453 shares at DKK 1,145.00,300 shares at DKK 1,147.50,85 shares at DKK 1,161.00,7 |
GMAB Price Returns
| 1-mo | -3.18% |
| 3-mo | 4.85% |
| 6-mo | 2.40% |
| 1-year | -30.28% |
| 3-year | -21.30% |
| 5-year | 75.26% |
| YTD | -9.01% |
| 2023 | -24.87% |
| 2022 | 7.13% |
| 2021 | -2.71% |
| 2020 | 82.09% |
| 2019 | 35.54% |
Loading social stream, please wait...